Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts

  • ulz_peter
    replied
    totally agree with BetterPrimate, if 30x fold coverage would mean 30 reads on every base it would be ok, but chances are very high that you miss bases, because there are no reads on that site.
    We do an approximate of 100x which yields good results for most bases.

    HOWEVER: If you are searching for somatic mutations you should consider some other aspects: are you sure your desired mutation will be present in 50% of all the alleles sequenced? Do you want to detect mutations that occur in some cells only? What is the possible level of contamination from non-tumor cells (immunological cells)?

    Leave a comment:


  • BetterPrimate
    replied
    Originally posted by arvi8689 View Post
    1)Generally how many exomes from different melanoma samples need to be done to get some satisfactory results?
    2)What coverage is essential for such a study? Initially I was thinking of around 30X but some papers have used nearly 100X. Will I be okay with 30X coverage of the exome?
    Your help is well appreciated.
    You might find that addressing more specific questions will be more rewarding to you.

    Can you define "satisfactory results"? Head on over to Pubmed and look at what others have done for some ideas e.g. the paper by Wei et. al PMC3161250

    Access and funding constraints probably will limit you to choosing from a few technology options e.g. you might be choosing between running a quarter plate vs half plate per sample on a SOLID. So it would be more fruitful to directly compare the options available to you.

    Coverage is a very indirect measure. The key question you probably want to ask is "what is the false negative rate?" for each option you have available. Put another way, what percentage of bases will have insufficient depth to make a variant call. If a causative variant is among those bases, you'll miss it. You can make your own decision on what is acceptable but also do your lit. search and be guided by what others have done.

    Leave a comment:


  • arvi8689
    replied
    Hey

    Thanks for the reply. I am looking for somatic mutations and not CNVs. One adv with my melanomas are that they r induced melanomas in model organism and they have not been exposed to UV. So I will not be getting any of the somatic mutations due to UV. You think in such a case I can go ahead with 10 samples.
    65x is the coverage you are using to look at CNVs. Will it be enough for looking at somatic mutations too?

    Leave a comment:


  • samesense
    replied
    I'm also doing melanoma exome analysis.

    1) I think this depends on what you are looking for, where your tumors are located, and where you plan to publish. If you want CNV patterns, I'm seeing those with ~30 tumor/normal pairs. For novel somatic SNVs common across the tumors, you will need many more pairs, as the only common SNVs I'm seeing with 30 have already been reported. For a pathway analysis, you might be able to get away with 10 pairs, but tumor location matters. Tumors with sun exposure can have 100s of somatic mutations, while mucosal melanomas can have less than 10, leaving you with few mutations to map to pathways. Also, if you want to publish in Science or Nature, you'll have to go big, say over 100 pairs if you want to compete.
    2) We have good results with an average of 65x coverage across the tumors using Illumina GAx, but there are plans to go higher.

    Leave a comment:


  • arvi8689
    started a topic Exome sequencing

    Exome sequencing

    Hey I am trying to sequence the melanoma exome to find somatic mutation involved in the melanoma. I am very new to this technique and I have some questions regarding this:

    1)Generally how many exomes from different melanoma samples need to be done to get some satisfactory results?
    2)What coverage is essential for such a study? Initially I was thinking of around 30X but some papers have used nearly 100X. Will I be okay with 30X coverage of the exome?

    Your help is well appreciated.

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Yesterday, 11:13 AM
0 responses
17 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, Yesterday, 10:48 AM
0 responses
18 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-15-2026, 10:52 AM
0 responses
36 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-14-2026, 05:39 AM
0 responses
42 views
0 reactions
Last Post SEQadmin2  
Working...